NIFTY 50 22795.9 ▼ (0.51%)
NIFTY NEXT 50 60466.8 ▼ (0.94%)
NIFTY 100 23274.05 ▼ (0.59%)
NIFTY MIDCAP 100 50486.2 ▼ (1.32%)
NIFTY SMALLCAP 100 15636.9 ▼ (0.7%)
NIFTY SMALLCAP 250 14683.4 ▼ (0.57%)
NIFTY MIDCAP SELECT 11198.9 ▼ (1.69%)
NIFTY TOTAL MARKET 11634.25 ▼ (0.67%)
NIFTY BANK 48981.2 ▼ (0.72%)
SENSEX 75311.06 ▼ (0.56%)
BSE BANKEX 55718.18 ▼ (0.82%)

Hester Biosciences Ltd : .Q4 .2024 .Quarterly Earnings: .YoY Sales Up .17.77. %, QoQ Up .18.32. %

May 11, 2024May 11, 2024| adminadmin| 0 Comments| 4:05 pm
Image is loading
Categories:

Share the post "Hester Biosciences Ltd : .Q4 .2024 .Quarterly Earnings: .YoY Sales Up .17.77. %, QoQ Up .18.32. %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company experienced a substantial growth of 17.77 % in the past year, substantial increase in net sales/revenue by 18.32 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 33.05 %. Marginal increase in other income during this quarter, up by 110.45%.
  • Profit over the Year and quarter: Significant improvement in profitability for Hester Biosciences Ltd. Notable increase of 11.92 % in net profit Year to Year, Hester Biosciences Ltd’s profitability increased by 59.08 % in this quarter.
  • EPS over the Year and quarter: EPS increased by 11.90 % Year to Year. EPS increased by 58.99 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of Hester Biosciences Ltd”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 67.299 Cr Rs. 66.983 Cr Rs. 79.255 Cr + 18.32 % + 17.77 %
Expenses Rs. 55.63 Cr Rs. 56.83 Cr Rs. 63.33 Cr + 11.44 % + 13.84 %
Operating Profit Rs. 11.67 Cr Rs. 10.15 Cr Rs. 15.93 Cr + 56.95 % + 36.5 %
OPM % 17.34 % 15.15 % 20.1 % + 4.95 % + 2.76 %
Other Income Rs. 3.48 Cr Rs. 2.2 Cr Rs. 4.63 Cr + 110.45 % + 33.05 %
Interest Rs. 1.37 Cr Rs. 2.19 Cr Rs. 6.94 Cr + 216.89 % + 406.57 %
Depreciation Rs. 5.37 Cr Rs. 3.75 Cr Rs. 3.74 Cr -0.27 % -30.35 %
Profit before tax Rs. 8.41 Cr Rs. 6.41 Cr Rs. 9.88 Cr + 54.13 % + 17.48 %
Tax % 33.32 % 45.95 % 36.99 % -8.96 % + 3.67 %
Net Profit Rs. 5.71 Cr Rs. 4.02 Cr Rs. 6.4 Cr + 59.2 % + 12.08 %
EPS in Rs Rs. 6.72 Rs. 4.73 Rs. 7.52 + 58.99 % + 11.9 %


Today, we’re looking at Hester Biosciences Ltd’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 17.77 %. However, it did see a marginal increase of 18.32 % from the previous quarter. Expenses ticked up slightly by 11.44 % quarter-on-quarter, aligning with the annual rise of 13.84 %. Operating profit, while up 36.5 % compared to last year, faced a quarter-on-quarter increase of 56.95 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.76 %, but an expansion of 4.95 % sequentially. Other income rose by 110.45 % compared to the last quarter, despite an annual growth of 33.05 %. Interest expenses surged remarkably by 216.89 % from the previous quarter, yet the year-over-year increase remains at a moderate 406.57 %. Depreciation costs fell by -0.27 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -30.35 %. Profit before tax grew annually by 17.48 % but saw an increase from the preceding quarter by 54.13 %.
Tax expenses as a percentage of profits increased slightly by 3.67 % compared to last year, with a more notable quarter-on-quarter decrease of -8.96 %. Net profit rose by 12.08 % year-on-year but experienced a 59.2 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 11.9 % but a quarterly rise of 58.99 %. In summary, Hester Biosciences Ltd’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 67.299 Cr Rs. 66.983 Cr Rs. 79.255 Cr + 18.32 % + 17.77 %
Expenses Rs. 55.63 Cr Rs. 56.83 Cr Rs. 63.33 Cr + 11.44 % + 13.84 %
Operating Profit Rs. 11.67 Cr Rs. 10.15 Cr Rs. 15.93 Cr + 56.95 % + 36.5 %
Net Profit Rs. 5.71 Cr Rs. 4.02 Cr Rs. 6.4 Cr + 59.2 % + 12.08 %
EPS in Rs Rs. 6.72 Rs. 4.73 Rs. 7.52 + 58.99 % + 11.9 %


In reviewing Hester Biosciences Ltd’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 17.77 % year-on-year growth, however, there was a minor increase of 18.32 % from the previous quarter. Expenses rose by 13.84 % compared to the previous year, with a 11.44 % increase quarter-on-quarter. Operating Profit surged by 36.5 % annually, and saw a 56.95 % increase from the last quarter.
Net Profit showed yearly increase of 12.08 %, and experienced a 59.2 % increase from the previous quarter. Earnings Per Share (EPS) rose by 11.9 % annually, however rose by 58.99 % compared to the last quarter. In essence, while Hester Biosciences Ltd exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Hester Biosciences Ltd “]

Related Post